Nemaura Medical Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Mar 31, 2023	FY2022 12 months to Mar 31, 2022	FY2021 12 months to Mar 31, 2021	FY2020 12 months to Mar 31, 2020	FY2019 12 months to Mar 31, 2019
Cash Flows from Operating Activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Loss on disposal of property and equipment
Mark-to-market foreign exchange revaluation
Accretion of debt discount
Monitoring fee interest expense added to notes payable
Fees for note amendments expense added to note payable
Inventory write-down
Impairment of intangible assets
Change in fair value of foreign exchange contract derivative liability
Change in fair value of warrant liability
Stock-based compensation
Other non-cash expenses
Changes in operating assets and liabilities:
Prepaid expenses
Prepaid expenses and other receivables
Inventory
Prepaid expenses and VAT receivable
Accrued interest receivable
Deposit on foreign exchange contract
Accounts payable
Liability due to related party
Accrued expenses and other liabilities
Receivable/payable to related parties
Other liabilities and accrued expenses
Deferred revenue

Net cash used in operating activities
Cash Flows from Investing Activities:
Purchase of property and equipment
Fixed rate savings account
Capitalized patent costs
Capitalized software development costs
Net cash used in investing activities

Cash Flows from Financing Activities:
Costs incurred in relation to ATM Financing
Costs incurred in relation to public offering
Proceeds from issuance of common shares
Gross proceeds from public offering
Costs incurred in relation to equity financing
Proceeds from warrant exercise
Gross proceeds from unit purchase option
Proceeds from issuance of notes payable
Debt issuance costs paid
Proceeds from issuance of long term debt, net of discount
Repayments of notes payable
Repayments of insurance financing
Net cash (used in) provided by financing activities

Net increase/(decrease)/ in cash
Net decrease in cash
Effect of exchange rate changes on cash
Cash at beginning of year
Cash at end of year
Supplemental cash flow information:
Interest paid
Taxes paid
Supplemental disclosure of non-cash financing activities:
Conversion of Series A preferred stock to common stock
Prepayment of equity compensation
Amount of insurance funded through note payable
Forgiveness of payable from a related party
Licenses acquired through stock issuance
Fair value of warrant liability recognized in connection with issuance of common shares
Monitoring fees added to notes payable

Comments